Search - tctmd.com

Displaying 1 - 20 of 92

Sort: Relevancy | Date

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

Evolocumab Gains Expanded Indication for Primary Prevention

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

FDA Approves Triple Therapy Polypill for High Blood Pressure

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

Coverage and Use of Impella and Watchman: A Tale of Four Countries

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

December 23, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

October 02, 2024

Little Pre- and Postmarket Testing for Most Recalled CV Devices

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

June 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

June 01, 2024

FDA Approves Bioresorbable Scaffold for BTK Lesions

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

Bempedoic Acid Gains CV Risk Reduction Indication

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

March 22, 2024

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

Top Endovascular News of 2023

News Daily News

Top Endovascular News of 2023

December 28, 2023

First Pulsed-Field Ablation System Gets FDA Approval

News Daily News

First Pulsed-Field Ablation System Gets FDA Approval

December 14, 2023

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

November 20, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.